Bayer has struck a deal to buy Perfuse Therapeutics for $300 million upfront and up to $2.15 billion tied to future milestones, picking up rights to Perfuse’s lead ophthalmology candidate, PER-001. The San Francisco biotech’s intravitreal implant delivers an endothelin antagonist that improves retinal blood flow and halts cell death in diseases such as glaucoma and diabetic retinopathy. Perfuse’s phase 2 data last year showed preliminary vision gains, modest but real progress in a field that rarely moves fast. Bayer, which markets the Regeneron-partnered anti-VEGF drug Eylea in Europe, called the program complementary to its current eye portfolio. Eylea remains Bayer’s biggest product at €3.1 billion ($3.7 billion) in 2025 sales, though growth has flattened as it edges toward maturity.
The acquisition reflects a clear push to rebuild Bayer’s ophthalmology pipeline as Eylea wanes. There’s still no phase 3 program for PER-001 listed on federal databases, indicating Bayer is buying flexibility, not an instant late-stage play. The math, $300 million upfront against more than $2 billion in milestones, makes that obvious. Bayer’s risk exposure is weighted to performance, a way to stay engaged while hedging against the early-stage odds that define ophthalmic innovation. Should the phase 2 improvements in glaucoma and diabetic retinopathy hold up, PER-001 would give Bayer a mechanism distinct from anti-VEGF options and stretch its presence in ocular disease well into the 2030s.
For ophthalmologists and payers, the logic tracks: Bayer wants to secure the next anchor product before the Eylea franchise fades completely, without waiting on cell therapy longshots like BlueRock’s photoreceptor effort. The watchpoints are execution and timing, how soon PER-001 moves into pivotal testing, how seamlessly Bayer folds Perfuse’s implant platform into global scale-up. If PER-001 moves forward, it may also spark fresh debate over pricing frameworks for novel mechanisms in retinal disease. And honestly, after years of anti-VEGF dominance, a new target class in the eye space just feels overdue. For broader ophthalmology drug profiles, see ClinicalRx.ai.
